(NASDAQ: VSTM) Verastem's forecast annual revenue growth rate of 76.86% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.6%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.68%.
Verastem's revenue in 2026 is $49,585,000.On average, 11 Wall Street analysts forecast VSTM's revenue for 2026 to be $9,168,735,493, with the lowest VSTM revenue forecast at $8,430,772,673, and the highest VSTM revenue forecast at $9,716,188,264. On average, 11 Wall Street analysts forecast VSTM's revenue for 2027 to be $16,619,541,344, with the lowest VSTM revenue forecast at $12,831,308,767, and the highest VSTM revenue forecast at $24,755,761,579.
In 2028, VSTM is forecast to generate $24,114,284,014 in revenue, with the lowest revenue forecast at $20,108,124,812 and the highest revenue forecast at $33,484,250,141.